China SXT Pharmaceuticals (SXTC) Debt to Equity (2019 - 2025)
China SXT Pharmaceuticals (SXTC) has 7 years of Debt to Equity data on record, last reported at $0.05 in Q1 2025.
- For Q1 2025, Debt to Equity rose 18.06% year-over-year to $0.05; the TTM value through Mar 2025 reached $0.05, up 18.06%, while the annual FY2025 figure was $0.05, 18.06% up from the prior year.
- Debt to Equity reached $0.05 in Q1 2025 per SXTC's latest filing, up from $0.04 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.76 in Q1 2021 and bottomed at $0.0 in Q1 2022.
- Average Debt to Equity over 5 years is $0.17, with a median of $0.04 recorded in 2024.
- Peak YoY movement for Debt to Equity: plummeted 99.91% in 2022, then soared 1106.91% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.76 in 2021, then crashed by 99.91% to $0.0 in 2022, then skyrocketed by 1106.91% to $0.01 in 2023, then surged by 411.84% to $0.04 in 2024, then increased by 18.06% to $0.05 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.05 in Q1 2025, $0.04 in Q1 2024, and $0.01 in Q1 2023.